In 2009, through the American Recovery and Reinvestment Act (ARRA), NINDS funded three consortia, to develop well characterized, publically available, induced pluripotent stem cell (iPSC) lines for familial forms of Parkinson’s disease (PD), Huntington’s disease (HD) and Amyotrophic Lateral Sclerosis (ALS). The first iPSC consortia workshop was held in February of 2010 and over the last 10 months, over 87 fibroblast lines (12 – ALS, 18-HD, 29-PD, 1-GBA, 3-FTD, 24-population or unaffected relative controls) and 25 iPSC lines have been developed and will be publically available through the NINDS repository at Coriell. The goals of the 2nd iPSC consortia workshop are to: 1) share progress; 2) methodologies; and 3) phenotypic analyses being utilized; 4) develop a standard report card for the iPSC lines developed; and 5) identify and resolve any remaining roadblocks that would delay successful completion of the proposed research in the accelerated two year time frame. The workshop will include an industry perspective and highlight collaborations and contributions from voluntary organizations in support of consortia effort.
Margaret Sutherland, Ph.D.
National Institute of Neurological Disorders
Phone: (301) 496-5680
Last Modified October 18, 2015